네오이뮨텍

950220KOSDAQ자연과학 및 공학 연구개발업

53.3 / 100

Reference Date: 2026-04-13

Financial Score20.5 / 40

News Sentiment18.8 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 14.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Neoimmune Tech is a biotech company specializing in T cell-based immunotherapy, with NT-I7, a long-acting T cell booster, as its core pipeline. The company is developing treatments for Acute Radiation Syndrome (ARS) and CAR-T combination therapies, while also holding an exclusive North American license for Endari®, an FDA-approved sickle cell disease treatment, to drive commercialization.

Number of Employees

40people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-64.24Industry Average -32.113.5Point

2.0x industry avg (excellent)

Debt Ratio

3.63Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼46.6% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -62.4% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 75

Positive
네오이뮨텍, 김태경 사내이사 대표이사로 선임
네오이뮨텍이 김태경 사내이사를 대표이사로 선임했으며, 김 신임 대표는 20년 이상 경력의 글로벌 임상개발 및 사업화 전문가입니다.
Positive
네오이뮨텍, CD19 CAR-T 병용 임상 NIT-126 첫 환자 초기...
네오이뮨텍이 CD19 CAR-T 치료제와의 병용을 평가하는 임상 1상(NIT-126)에서 첫 환자 초기 투여를 완료하며 임상 개발을 본격화했습니다.
Positive
네오이뮨텍, NT?I7 기반 감염 면역 회복 연구…서울대 조남혁 교수팀...
네오이뮨텍이 서울대학교 의과대학 조남혁 교수 연구팀과 함께 NT-I7을 활용한 조혈 편향 개선 및 감염 면역 회복 메커니즘 규명을 위한 공동 연구를 진행합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 483Won52-week high 1,46552-week low 472

1-month return1.0Point

1m -14.36% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주식매수선택권부여에관한신고2026-03-27
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral대표이사변경2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral기업설명회(IR)개최2026-03-24